

PROVIDER BULLETIN

PROVIDER INFORMATION



February 8, 2023

Commercial Pharmacy Benefit Exclusion for Briumvi™, Hemgenix®, Rebyota™, and Sunlenca® Injection

Effective **February 8, 2023**, the drugs listed in the table below will be excluded from pharmacy benefit coverage due to clinician-administered route of administration and may be available for medical benefit coverage for subscribers who are eligible.

Drug Name
Briumvi™ (ublituximab-xiiy) solution for intravenous (IV) infusion
Hemgenix® (etranacogene dezaparvovec-drlb) suspension for intravenous (IV) infusion
Rebyota™ (fecal microbiota, live–jslm) suspension for rectal administration
Sunlenca® (lenacapavir sodium injection) solution for subcutaneous injection

Products Impacted

This applies to the commercial line of business.

Questions?

Please contact provider services at **(651) 662-5200** or **1-800-262-0820**.